Brexit is not quite the done deal, even if the impetus towards it seems all but unstoppable. Seen through this lens, the UK medtech industry association, ABHI, sees little merit in analyzing the potential benefits and drawbacks of the UK's decision to leave the EU. Rather, it prefers now to get on with helping to shape the post-Brexit landscape for the UK medtech industry.
UK Medtechs Look Beyond Brexit To Long-Term Life-Science Strategy
The UK medtech industry is looking past Brexit to a time when the government's new Life Science Strategy has gone live. It also seeks better access to the NHS for medtech companies developing and launching innovations as the UK makes its own way in the world as a former EU member state.
More from United Kingdom
• By
AI systems used in healthcare are vulnerable to adversarial cyberattacks, which are a growing concern, said Atif Azad, a professor of AI at Birmingham City University. Azad’s research group has developed a method that trains AI to become more resilient to cyber threats through the use of random image adjustments.
• By
The UK’s “New Approach” to regulation has created a lot of noise, but what’s the end product? asks Taylor Wessing partner Alison Dennis, who says the UK medtech regulator should look afresh at the EU’s ready-made solution.
• By
Medtech has not yet been spared from the Trump administration’s trade tariffs, which, for UK exporters will be 10% – half the rate applied to EU27 exporters.
• By
Cambridge, UK-based breath biopsy company Owlstone Medical will apply its volatile organic compound analysis platform in an attempt to develop a test for the identification and monitoring of pseudomonas aeruginosa in patients with cystic fibrosis.
More from Europe
• By
Biomedical Alliance’s Tom Melvin is on a mission to assist the European Commission comprehend the clinical gaps during its ‘targeted evaluation’ of the EU's medtech regulations and the pivotal role the EMA could play.
• By
The UK’s “New Approach” to regulation has created a lot of noise, but what’s the end product? asks Taylor Wessing partner Alison Dennis, who says the UK medtech regulator should look afresh at the EU’s ready-made solution.
• By
US President Trump has imposed sweeping tariffs that encompass medtech. These are expected to drive up costs, disrupt supply chains and hinder innovation, likely driving the EU to seek new trade partnerships to mitigate the impact.